sharesgurusharesguru
  • Stocks
  • Ai Screener
  • Sectors
  • Watchlist
LoginSign Up
sharesguru
  • Home
  • Stocks
  • Ai Screener
  • Sectors
  • Watchlist
  • Profile
  • Contact Us
LoginSign Up
sharesguru

Discover the joy of investing.

All the financial data and tools you need, at one place.

Navigation

  • Home
  • Stocks
  • Sectors

Tools

  • Ai Screener
  • Watchlists

Company

  • Contact

Legal

  • Privacy Policy
  • Terms of Service
Copyright © 2025 Knowtilus Technologies Pvt. Ltd.
SummaryLatest NewsSector ComparisonEarnings ReportRevenue & GrowthPeersIncome StatementBalance SheetCash Flow
GRANULES logo

GRANULES - Granules India Ltd. Share Price

Pharmaceuticals & Biotechnology
Sharesguru Stock Score

GRANULES

66/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹631.95-3.55(-0.56%)
Market Closed as of Apr 10, 2026, 15:30 IST
Pros

Size: Market Cap wise it is among the top 20% companies of india.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Past Returns: Outperforming stock! In past three years, the stock has provided 27.3% return compared to 10.7% by NIFTY 50.

Balance Sheet: Strong Balance Sheet.

Smart Money: Smart money has been increasing their position in the stock.

Profitability: Recent profitability of 11% is a good sign.

Cons

No major cons observed.

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Sharesguru Stock Score

GRANULES

66/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

Valuation

Market Cap15.42 kCr
Price/Earnings (Trailing)28.27
Price/Sales (Trailing)3.02
EV/EBITDA14.9
Price/Free Cashflow46.92
MarketCap/EBT21.41
Enterprise Value16.45 kCr

Fundamentals

Revenue (TTM)5.11 kCr
Rev. Growth (Yr)21.1%
Earnings (TTM)545.48 Cr
Earnings Growth (Yr)27.7%

Profitability

Operating Margin14%
EBT Margin14%
Return on Equity13.7%
Return on Assets7.86%
Free Cashflow Yield2.13%

Growth & Returns

Price Change 1W-2.5%
Price Change 1M6.7%
Price Change 6M10.1%
Price Change 1Y27%
3Y Cumulative Return27.3%
5Y Cumulative Return14.5%
7Y Cumulative Return28%
10Y Cumulative Return17.9%

Cash Flow & Liquidity

Cash Flow from Investing (TTM)-691.29 Cr
Cash Flow from Operations (TTM)866.57 Cr
Cash Flow from Financing (TTM)-92.51 Cr
Cash & Equivalents608.61 Cr
Free Cash Flow (TTM)294.87 Cr
Free Cash Flow/Share (TTM)12.15

Balance Sheet

Total Assets6.94 kCr
Total Liabilities2.96 kCr
Shareholder Equity3.98 kCr
Current Assets3.09 kCr
Current Liabilities2.42 kCr
Net PPE2.61 kCr
Inventory1.49 kCr
Goodwill11.65 Cr

Capital Structure & Leverage

Debt Ratio0.24
Debt/Equity0.41
Interest Coverage5.82
Interest/Cashflow Ops9.67

Dividend & Shareholder Returns

Dividend/Share (TTM)1.5
Dividend Yield0.27%
Shares Dilution (1Y)0.10%
Shares Dilution (3Y)0.30%
Pros

Size: Market Cap wise it is among the top 20% companies of india.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Past Returns: Outperforming stock! In past three years, the stock has provided 27.3% return compared to 10.7% by NIFTY 50.

Balance Sheet: Strong Balance Sheet.

Smart Money: Smart money has been increasing their position in the stock.

Profitability: Recent profitability of 11% is a good sign.

Cons

No major cons observed.

The Good, Bad and Ugly
Growth
Measures how quickly a company is expanding through metrics like revenue growth, earnings growth, and cash flow growth over time. Strong growth can indicate future potential.
Profitability
Shows how efficiently a company turns business activities into profit, using metrics like profit margins, return on equity (ROE), and return on assets (ROA).
Size
Indicates the company's market presence through metrics like market capitalization, total assets, and revenue. Size can influence stability and market influence.
Dilution Rank
Tracks how much the company's shares have increased or decreased over time. Lower dilution means existing shareholders maintain stronger ownership stakes.
Balance Sheet
Evaluates the company's financial health by analyzing assets, debts, and equity. A strong balance sheet indicates financial stability and flexibility.
Momentum
Measures the strength and speed of price movements, showing whether the stock is gaining or losing market favor over different time periods.
Technicals
Analyzes price patterns, trading volumes, and other market indicators to identify potential trading opportunities and market trends.
Smart Money
Tracks the investment activities of institutional investors, hedge funds, and other large financial players who often have deep research capabilities.
Insider Trading
Monitors buying and selling of company shares by executives, directors, and other insiders who may have unique insights into the company's prospects.

Investor Care

Dividend Yield0.27%
Dividend/Share (TTM)1.5
Shares Dilution (1Y)0.10%
Earnings/Share (TTM)22.48

Financial Health

Current Ratio1.28
Debt/Equity0.41

Technical Indicators

RSI (14d)69.7
RSI (5d)55.75
RSI (21d)62.33
MACD SignalBuy
Stochastic Oscillator SignalSell
SharesGuru SignalBuy
RSI SignalHold
RSI5 SignalHold
RSI21 SignalHold
SMA 5 SignalBuy
SMA 10 SignalBuy
SMA 20 SignalBuy
SMA 50 SignalBuy
SMA 100 SignalBuy

Summary of Latest Earnings Report from Granules India

Summary of Granules India's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Share Holdings

Understand Granules India ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Share Holding Details

Shareholder NameHolding %
KRISHNA PRASAD CHIGURUPATI30.99%
LIFE INSURANCE CORPORATION OF INDIA5.22%
CHIGURUPATI UMA DEVI3.73%
SBI LIFE INSURANCE CO. LTD3.3%
KOTAK MAHINDRA LIFE INSURANCE COMPANY LTD.1.74%
TYCHE INVESTMENTS PRIVATE LIMITED1.43%
SMALLCAP WORLD FUND, INC1.39%
BASAVA SANKARA RAO KOLLI1.17%
360 ONE PIPE FUND1.1%
PRAGNYA CHIGURUPATI0.74%
CHIGURUPATI PRIYANKA0.73%
SANTHI SREE RAMANAVARAPU0.35%
SUSEELA DEVI CHIGURUPATI0.03%
NIKHILA REDDY YEDAGURI0.01%
HARSHA CHIGURUPATI0%
KALIDINDI ABINAV VARMA0%
VENKATA MAHESH KRISHNA NARRA0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Granules India Better than it's peers?

Detailed comparison of Granules India against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker
Name
Mkt Cap
Revenue
Price %, 1M
Returns, 1Y
P/E
P/S
Rev 1-Yr
Inc 1-Yr
SUNPHARMASun Pharmaceutical Industries3.97 LCr58.94 kCr-9.40%+0.20%36.376.74--
DIVISLABDivi's Lab1.62 LCr10.75 kCr-3.70%+13.60%65.5515.11--
DRREDDYDr. Reddy's Lab1.03 LCr36.09 kCr-7.30%+12.30%18.382.84--
CIPLACipla99.34 kCr29.37 kCr-7.50%-13.10%21.843.38--
AUROPHARMAAurobindo Pharma78.54 kCr33.73 kCr+3.60%+27.80%22.522.33--

Sector Comparison: GRANULES vs Pharmaceuticals & Biotechnology

Comprehensive comparison against sector averages

Comparative Metrics

GRANULES metrics compared to Pharmaceuticals

CategoryGRANULESPharmaceuticals
PE28.2733.70
PS3.024.65
Growth14.2 %8 %
0% metrics above sector average
Key Insights
  • 1. GRANULES is NOT among the Top 10 largest companies in Pharmaceuticals.
  • 2. The company holds a market share of 1.1% in Pharmaceuticals.
  • 3. In last one year, the company has had an above average growth that other Pharmaceuticals companies.

Income Statement for Granules India

Consolidated figures (in Rs. Crores) /
Description(%) Q/QMar-2025Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020
Revenue From Operations-0.5%4,4824,5064,5123,7653,2382,599
Revenue From Operations-------
Other Income252.9%134.414182737
Other Income-------
Total Income-0.4%4,4954,5114,5263,7833,2642,635
Total Income-------
Cost of Materials-21.9%1,7252,2082,3532,0361,5901,315
Cost of Materials-------
Employee Expense10.4%660598472401408259
Employee Expense-------
Finance costs-2.9%10310656232627
Finance costs-------
Depreciation and Amortization9.2%226207184159151137
Depreciation and Amortization-------
Other expenses11.7%1,1511,031819758583533
Other expenses-------
Total Expenses-2.5%3,8653,9643,8393,2252,5602,237
Total Expenses-------
Profit Before exceptional items and Tax15%629547687558704398
Profit Before exceptional items and Tax-------
Exceptional items before tax-31000028
Total profit before tax20.7%660547687558704426
Total profit before tax-------
Current tax11%183165177138195126
Current tax-------
Deferred tax-3.5%-24.15-23.31-6.67.04-40.47-9.98
Deferred tax-------
Total tax12.1%159142171145155116
Total tax-------
Total profit (loss) for period24%502405517413549335
Total profit (loss) for period-------
Other comp. income net of taxes36.8%27205740-26.162.18
Other comp. income net of taxes-------
Total Comprehensive Income24.2%529426574453523338
Total Comprehensive Income-------
Earnings Per Share, Basic25.2%20.6916.7321.0516.6622.0513.19
Earnings Per Share, Basic-------
Earnings Per Share, Diluted25.2%20.6816.722116.621.9513.15
Earnings Per Share, Diluted-------
Description(%) Q/QDec-2025Sep-2025Jun-2025Mar-2025Dec-2024Sep-2024
Revenue From Operations7%1,3881,2971,2101,1971,138967
Other Income-115.8%-3.64-1.15161.925.683.26
Total Income6.8%1,3841,2961,2261,1991,143970
Cost of Materials6.2%529498429435445362
Employee Expense3.2%226219203169168159
Finance costs0%292924242726
Depreciation and Amortization2.8%747269645753
Other expenses-0.8%352355336338304237
Total Expenses5.5%1,1821,1201,0561,033991841
Profit Before exceptional items and Tax14.9%202176170167153128
Exceptional items before tax-00-25.913100
Total profit before tax14.9%202176145198153128
Current tax44%735138623731
Deferred tax-232.5%-20.88-5.58-6.24-16.26-1.75-0.13
Total tax15.9%524532463531
Total profit (loss) for period14.6%15013111315211897
Other comp. income net of taxes-52.6%19391911103.71
Total Comprehensive Income-0.6%169170132163128101
Earnings Per Share, Basic18.5%6.195.384.646.274.854.01
Earnings Per Share, Diluted18.5%6.195.384.646.274.854.01
Standalone figures (in Rs. Crores) /
Description(%) Q/QMar-2025Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020
Revenue From Operations-19.3%3,0303,7553,9313,2383,1352,310
Other Income736.8%415.789.93181426
Total Income-18.4%3,0713,7613,9413,2563,1492,336
Cost of Materials-28.7%1,3741,9272,1001,8641,5021,253
Employee Expense0.3%382381330283318193
Finance costs-12.7%637239162427
Depreciation and Amortization1.4%146144146126118102
Other expenses11%739666601553446401
Total Expenses-15.7%2,6743,1703,2772,7362,4161,944
Profit Before exceptional items and Tax-33.1%396591664520733392
Exceptional items before tax-310000161
Total profit before tax-27.8%427591664520733553
Current tax-27.3%110151170134197122
Deferred tax-179.3%-1.994.77-5.05-0.38-16.97-13.27
Total tax-30.5%108155165133180109
Total profit (loss) for period-26.9%319436499387553444
Other comp. income net of taxes-58.5%4.088.43-4.6914-5.51-27.05
Total Comprehensive Income-27.3%323444494400547417
Earnings Per Share, Basic-28.4%13.171820.3215.622.1817.47
Earnings Per Share, Diluted-28.4%13.1717.9920.315.5522.0917.41
Description(%) Q/QDec-2025Sep-2025Jun-2025Mar-2025Dec-2024Sep-2024
Revenue From Operations0.3%895892810768842568
Other Income59.9%127.8813305.612.78
Total Income0.8%907900823799848571
Cost of Materials10.6%388351370342349281
Employee Expense1%105104106979690
Finance costs-12.5%151714131715
Depreciation and Amortization0%414140383835
Other expenses0.5%204203204211199143
Total Expenses2.6%757738720703729515
Profit Before exceptional items and Tax-7.5%1501621049611956
Exceptional items before tax-00-12.163100
Total profit before tax-7.5%1501629112711956
Current tax-7.1%404323392713
Deferred tax4.6%-1.69-1.82-1.03-6.181.651.48
Total tax-5%394122332815
Total profit (loss) for period-7.5%11212169949041
Other comp. income net of taxes69.6%-2.1-9.21-0.8314-10.95-0.79
Total Comprehensive Income-1.8%109111691087941
Earnings Per Share, Basic-9.3%4.64.972.863.883.721.71
Earnings Per Share, Diluted-9.3%4.64.972.863.883.721.71

Balance Sheet for Granules India

Consolidated figures (in Rs. Crores) /
Description(%) Q/QSep-2025Mar-2025Sep-2024Mar-2024Sep-2023Mar-2023
Cash and cash equivalents30.8%609466209381296292
Loans, current-000000
Total current financial assets-10%1,3861,5409451,3751,3301,264
Inventories10.8%1,4881,3431,3951,3011,2801,149
Total current assets-0.9%3,0873,1152,6052,9052,7922,574
Property, plant and equipment17.8%2,6122,2171,8931,8561,7871,631
Capital work-in-progress60.8%702437411260219228
Goodwill-1200000
Non-current investments-100.8%0.842222222121
Loans, non-current-000000
Total non-current financial assets-50%224340383836
Total non-current assets23%3,8573,1372,8272,6162,4732,330
Total assets11.1%6,9446,2535,4335,5215,2654,905
Borrowings, non-current1.9%3183121576998149
Total non-current financial liabilities1.3%477471236152184219
Provisions, non-current67.7%533244383329
Total non-current liabilities1.9%544534314213228256
Borrowings, current35.6%1,3209748531,1541,187910
Total current financial liabilities33.9%2,3111,7261,6482,0392,0311,771
Provisions, current16.1%373212121115
Current tax liabilities41.2%2518195.611013
Total current liabilities20.7%2,4172,0031,6922,0822,0691,814
Total liabilities16.7%2,9612,5372,0052,2952,2972,070
Equity share capital0%242424242424
Non controlling interest-0000-0
Total equity7.2%3,9833,7163,4273,2262,9672,835
Total equity and liabilities11.1%6,9446,2535,4335,5215,2654,905
Standalone figures (in Rs. Crores) /
Description(%) Q/QSep-2025Mar-2025Sep-2024Mar-2024Sep-2023Mar-2023
Cash and cash equivalents699.3%1,20815281223237182
Loans, current-7.75002.7300
Total current financial assets-0.3%1,4641,4691,2631,8661,7651,578
Inventories-2.9%629648737579649593
Total current assets-1.2%2,2592,2872,2142,6342,5762,318
Property, plant and equipment1.9%1,3861,3601,2681,2661,2311,256
Capital work-in-progress-0.8%11912084538763
Non-current investments20.7%1,5471,282987941818677
Loans, non-current-00006.0412
Total non-current financial assets20.3%1,5631,2991,003957840713
Total non-current assets11.1%3,1842,8652,4442,3722,2772,185
Total assets5.6%5,4435,1524,6585,0064,8534,503
Borrowings, non-current-0005098149
Total non-current financial liabilities1.2%87865.2357106157
Provisions, non-current-3.2%313244383329
Total non-current liabilities-3.4%14314883126170210
Borrowings, current14.1%9228087271,0041,054762
Total current financial liabilities8.8%1,6811,5451,3351,7281,7801,561
Provisions, current16.7%363112121115
Current tax liabilities109.1%24126.014.229.019.01
Total current liabilities9.5%1,7521,6001,3631,7691,8141,594
Total liabilities8.3%1,8941,7491,4471,8951,9841,804
Equity share capital0%242424242424
Total equity4.3%3,5493,4033,2113,1112,8692,699
Total equity and liabilities5.6%5,4435,1524,6585,0064,8534,503

Cash Flow for Granules India

Consolidated figures (in Rs. Crores) /
Description(%) Q/QMar-2025Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020
Finance costs-2.9%1031065623--
Change in inventories84.8%-20.57-140.73-135.47-184.03--
Depreciation9.2%226207184159--
Unrealised forex losses/gains140%4.5-7.74-9.15-11.97--
Adjustments for interest income52.2%3.742.84.5113--
Share-based payments-38.9%00.281.291.62--
Net Cashflows from Operations60.4%1,010630915477--
Income taxes paid (refund)-24.3%144190176145--
Net Cashflows From Operating Activities97.7%867439739332--
Proceeds from sales of PPE-233.3%01.750.210.98--
Purchase of property, plant and equipment50.3%572381411398--
Proceeds from sales of investment property-1.7000--
Interest received46.9%3.62.775.0512--
Other inflows (outflows) of cash-939.3%-124.89162144.48--
Net Cashflows From Investing Activities-91.7%-691.29-360.16-191.36-380.11--
Proceeds from issuing shares85.2%53.162.783.71--
Payments to acquire or redeem entity's shares-003110--
Proceeds from borrowings21.9%2,4011,97046349--
Repayments of borrowings28.9%2,3411,8169395--
Payments of lease liabilities70%1811135.4--
Dividends paid0%36361937--
Interest paid0%1031035324--
Other inflows (outflows) of cash-00-0.50--
Net Cashflows from Financing Activities-1504.1%-92.517.66-440.29190--
Effect of exchange rate on cash eq.-23.5%2.242.62-0.250.94--
Net change in cash and cash eq.-5.6%8590107143--
Standalone figures (in Rs. Crores) /
Description(%) Q/QMar-2025Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020
Finance costs-12.7%63723916--
Change in inventories-606.2%-69.8715-2.67-129.05--
Depreciation1.4%146144146126--
Unrealised forex losses/gains134%4.07-8.04-9.81-11.99--
Adjustments for interest income-42%2.122.934.6413--
Share-based payments-38.9%00.281.191.94--
Net Cashflows from Operations93%914474841423--
Income taxes paid (refund)-42.3%91157177143--
Net Cashflows From Operating Activities160.1%823317664280--
Cashflows used in obtaining control of subsidiaries59.9%34021300--
Proceeds from sales of PPE-233.3%01.750.20.98--
Purchase of property, plant and equipment76.5%211120212325--
Proceeds from sales of investment property-6.22000--
Interest received-33.5%2.112.673.8412--
Other inflows (outflows) of cash-142.9%-9.7226111-6.42--
Net Cashflows From Investing Activities-82.1%-552.43-302.98-96.45-318.45--
Proceeds from issuing shares85.2%53.162.783.21--
Payments to acquire or redeem entity's shares-003110--
Proceeds from borrowings7.5%2,0991,9520303--
Repayments of borrowings28.9%2,3411,81614995--
Payments of lease liabilities104.5%9.144.9804.72--
Dividends paid0%36361937--
Interest paid-21.1%57723717--
Net Cashflows from Financing Activities-1463.3%-339.8226-519.47151--
Effect of exchange rate on cash eq.-1012.5%-1.191.24-0.250.94--
Net change in cash and cash eq.-279.3%-70.744148114--

What does Granules India Ltd. do?

Pharmaceuticals•Healthcare•Small Cap

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationlly. The company's APIs in various therapeutic categories include anti-retrovirals, anti-hypertensives, anti-histamines, anti-infectives, analgesics, anti-coagulants, anti-fibriotics, and platelet inhibitors. It also offers tablets, caplets, and press-fit capsules in bulk, blister packs, and bottles; high potent products; and other products for oncology. Granules India Limited was founded in 1984 and is based in Hyderabad, India.

Industry Group:Pharmaceuticals & Biotechnology
Employees:4,057
Website:www.granulesindia.com

Important Disclosure & Data Context

This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.

Performance Comparison

GRANULES vs Pharmaceuticals (2021 - 2026)

GRANULES leads the Pharmaceuticals sector while registering a 25.9% growth compared to the previous year.